Clinical trials
Phase 1 Ovarian Neoplasms trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
66 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2014 | 1 |
| 2015 | 3 |
| 2017 | 5 |
| 2018 | 3 |
| 2019 | 4 |
| 2020 | 3 |
| 2021 | 7 |
| 2022 | 9 |
| 2023 | 7 |
| 2024 | 7 |
| 2025 | 9 |
| 2026 | 7 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 20 |
| Unknown status | 20 |
| Completed | 12 |
| Not yet recruiting | 7 |
| Active, not recruiting | 4 |
| Terminated | 2 |
| Suspended | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Chongqing Precision Biotech Co., Ltd | 5 |
| Jiangsu HengRui Medicine Co., Ltd. | 4 |
| Eli Lilly and Company | 3 |
| Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd | 3 |
| Impact Therapeutics, Inc. | 2 |
| Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2 |
| Shanghai Gynecologic Oncology Group | 2 |
| Shanghai Yunying Medical Technology | 2 |
| West China Hospital | 2 |
| Zhejiang University | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Ovarian Neoplasms | 66 |
| Breast Neoplasms | 21 |
| Uterine Cervical Neoplasms | 14 |
| Lung Neoplasms | 11 |
| Neoplasm Metastasis | 11 |
| Colorectal Neoplasms | 10 |
| Pancreatic Neoplasms | 10 |
| Prostatic Neoplasms | 10 |
| Endometrial Neoplasms | 9 |
| Stomach Neoplasms | 9 |
Trials
Showing 1 to 25 of 66. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.